HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Galectin Therapeutics (NASDAQ:GALT) and maintained an $11 price target.
August 15, 2023 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Galectin Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $11.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Galectin Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100